Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance).

Kostandinos SiderasDavid W HillmanKarthik GiridharBrenda F GinosRichard C TenglinHeshan LiuBeiyun ChenWinston TanGerald G GrossRex B MowatAmylou C DueckEdith A PerezAlvaro Moreno-Aspitia

Published in: The oncologist (2022)

Pixantrone has insufficient activity in the second- and third-line MBC setting. It appears, however, to have limited cardiotoxicity. (ClinicalTrials.gov ID: NCT01086605).

Keyphrases

phase ii study
metastatic breast cancer
open label
placebo controlled
double blind
phase iii
phase ii
clinical trial
locally advanced
study protocol
randomized controlled trial